AI Article Synopsis
- - The study examined the link between cardiovascular events (CVE) and bronchiectasis exacerbations, showing that the risk of CVE increases during and after these episodes.
- - Analyzed patient data from 250 individuals, the results revealed that 29.6% experienced a CVE during follow-up, and 37.2% died, with certain factors like age and COPD heightening the risk of CVE.
- - The findings suggest that demographic factors and existing health conditions are significant predictors of CVE following bronchiectasis exacerbations, which negatively impacts long-term survival outcomes.
Article Abstract
Background: Population-based and retrospective studies have shown that risk for cardiovascular events such as arrythmias, ischemic episodes, or heart failure, increase during and after bronchiectasis exacerbations.
Research Question: What are the risk factors for cardiovascular events (CVE) during and after bronchiectasis exacerbations and their impact on mortality?
Study Design And Methods: This was a post hoc retrospective analysis of a prospective observational study of 250 patients with bronchiectasis at two tertiary care hospitals. Only the first exacerbation was considered for each patient, collecting demographic, comorbidity, and severity data. The main outcomes were the appearance of CVE and mortality. Risk factors for CVE were analyzed using a semi-competing risks model.
Results: During a median follow-up of 35 months, 74 (29.6%) patients had a CVE and 93 (37.2%) died. Semi-competing risk analysis indicated that age, arterial hypertension, COPD, and potentially severe exacerbations significantly increased the risk for developing CVE. Compared with patients without CVE, those with CVE had higher mortality.
Interpretation: Demographic factors and comorbidities are risk factors for the development of CVE after an acute exacerbation of bronchiectasis. The appearance of CVE worsens long-term prognosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.chest.2021.10.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Egg Consumption and Mortality: A Prospective Cohort Study of Australian Community-Dwelling Older Adults.
Nutrients
January 2025
School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia.
Background/objectives: Egg consumption in adults has been linked with a modestly increased risk of all-cause and CVD mortality. However, evidence on adults aged 65 y+ is limited. The objective of this study was to investigate the association between egg intake and mortality in community-dwelling older adults.
View Article and Find Full Text PDFImpact in Clinical Practice of the European Medicines Agency Health Alert About the Restriction of the Use of JAK Inhibitors.
Pharmaceuticals (Basel)
December 2024
Department of Rheumatology, Hospital Universitario Infanta Sofía, FIIB HUIS HHEN, Universidad Europea, 28702 Madrid, Spain.
Janus kinase inhibitors (JAKi) have revolutionized the treatment of various inflammatory and immune disorders. Concerns about the potential increased risk of major adverse cardiovascular events (MACEs) associated with JAKi use led to a European Medicines Agency (EMA) health alert recommending restricting the use of JAKi in high-risk populations. This study aims to determine the proportion of patients who developed any cardiovascular, ischemic, neoplastic, or thrombotic adverse event in a cohort of patients receiving, or who have received, JAKi treatment between January 2017 and September 2023.
View Article and Find Full Text PDFScreening for Subclinical Atherosclerosis in Patients with Familial Hypercholesterolemia: Insights and Implications.
J Clin Med
January 2025
Institute of Cardiology, Istanbul University-Cerrahpaşa, 34098 Istanbul, Türkiye.
: Familial hypercholesterolemia (FH) is a monogenic dyslipidemia that leads to early cardiovascular events. Subclinical atherosclerosis refers to the formation of atheromatous plaques in arterial beds before any clinical events. In our study, we investigated the presence, extent, and independent predictors of subclinical atherosclerosis among patients diagnosed with FH.
View Article and Find Full Text PDFComprehensive Review of Lipid Management in Chronic Kidney Disease and Hemodialysis Patients: Conventional Approaches, and Challenges for Cardiovascular Risk Reduction.
J Clin Med
January 2025
Department of Medicine, Division of Nephrology, Northwell Health, Staten Island University Hospital, Staten Island, NY 10305, USA.
: Lipid disorders are very prevalent in patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD), leading to heightened cardiovascular risk. This review examines the effectiveness of lipid-lowering agents in these populations and explores gaps in the current research. The goal of this review is to assess the efficacy of lipid-lowering therapies in CKD and ESRD patients and identify future research needs.
View Article and Find Full Text PDFClinical Outcomes of Catheter Ablation for Atrial Fibrillation in Patients with Acute Decompensated Heart Failure.
J Clin Med
January 2025
Department of Cardiology, Saitama Medical University International Medical Center, Saitama 350-1298, Japan.
: The prognosis of acute decompensated heart failure (ADHF) and heart failure (HF) with atrial fibrillation (AF) has been dismal. This study was performed to investigate the clinical outcomes of catheter ablation (CA) performed in patients with concurrent ADHF and AF. : We retrospectively analyzed ADHF patients with AF who were admitted to our institution from 2007 to 2017.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!